ClinicalTrials.gg
TerminatedNCT00539838BEGINUpdated Sep 17, 2020Results posted

A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)

A Phase 3 interventional study of Prednisone and Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate) in Systemic Lupus Erythematosus, sponsored by Genentech, Inc.. Terminated. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2020-09-17.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated prematurely when the decision was made that ocrelizumab was not likely to benefit this patient population.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche — 2 open to participants now, 4 under way, 1 of them phase 3. Lupus Erythematosus, Systemic · Hoffmann-La Roche.

Enrollment
10th of 14
33 · median 65
Started
2007
with 1 other
Phase 3
4 of 14
none open now
Registered
3rd of 14
by date

Among the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche, this one is the 10th largest by enrollment, is one of 2 that started in 2007, is one of 4 in phase 3, and was the 3rd registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

2 of the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This is a Phase III, randomized, double blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of ocrelizumab compared to placebo when combined with a single stable background immunosuppressive medication and a corticosteroid regimen in patients with moderately to severely active systemic lupus erythematosus, who do not have moderate to severe glomerulonephritis.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • SLE
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 16 years or above at the time of screening
  • Diagnosis of SLE
  • Active disease at screening

Exclusion criteria

Exclusion Criteria:

  • Presence of active moderate to severe glomerulonephritis
  • Currently active retinitis, poorly controlled seizure disorder, acute confusional state, myelitis, stroke or stroke syndrome, cerebellar ataxia, or dementia
  • Lack of peripheral venous access
  • Pregnancy or breast feeding mothers
  • History of severe allergic or anaphylactic reactions to humanized, chimeric or murine monoclonal antibodies or i.v. immunoglobulin
  • Known severe chronic pulmonary disease
  • Evidence of significant or uncontrolled concomitant diseases in any organ system not related to SLE, which, in the investigator's opinion, would impair patient participation
  • Concomitant condition which has required treatment with systemic (excluding topical or inhaled) at any time in the 52 weeks prior to screening
  • Known or chronic active or chronic active infection
  • Known active infection of any kind (but excluding fungal infection of nail beds or oral thrush which has resolved before Day 1) within 30 days prior to Day 1. In addition, any major episode of infection requiring hospitalization or treatment with intravenous anti-infectives in the 30 days prior to Day 1 or oral anti-infectives in the 14 days prior to Day 1
  • History of serious recurrent or chronic infection
  • History of cancer (except basal cell carcinoma of the skin that has been excised and cured)
  • History of alcohol or drug abuse in the 52 weeks prior to screening
  • Major surgery in the 4 weeks prior to screening excluding diagnostic surgery
  • Previous treatment with CAMPATH-1H
  • Previous treatment with a BAFF directed treatment in the 12 months prior to screening
  • Previous treatment with a B-cell targeted therapy other than one directed at BAFF
  • Treatment with any agent, other than those above, in the 28 days prior to screening or five half-lives of the investigational drug (whichever is longer)
  • Receipt of any in the 6 weeks prior to Day 1
  • Intolerance or to oral or i.v. corticosteroids
  • Treatment with a second or immunomodulatory drug in the 8 weeks prior to Day 1
  • Prednisone dose of ≥ 0.7 mg/kg/day (or equivalent) for > 7 of the previous 30 days prior to screening
  • Treatment with cyclophosphamide or a calcineurin inhibitor in the 12 weeks prior to screening
  • Positive hepatitis BsAg or hepatitis C serology. Patients who are HBsAg negative but HBcAb positive may be enrolled with a negative DNA test
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Ocrelizumab 1000 mg

    Ocrelizumab was administered i.v. at a dose on Days 1 and 15, followed by 1000 mg i.v. at Week 16 and then every 16 weeks

    Drug: Prednisone · Drug: Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate) · Drug: Methylprednisolone · Drug: Ocrelizumab

  • Experimental
    Ocrelizumab 400 mg

    Ocrelizumab was administered at a dose 400 mg i.v. on Days 1 and 15, followed by 400 mg i.v. at Week 16 and then every 16 weeks

    Drug: Prednisone · Drug: Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate) · Drug: Methylprednisolone · Drug: Ocrelizumab

  • Placebo comparator
    Placebo

    Placebo infusions were administered on Days 1 and 15, followed by placebo infusion at Week 16 and then every 16 weeks

    Drug: Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate) · Drug: Placebo

Interventions

  • Oral repeating dose

  • DrugImmunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)

    Oral repeating dose

  • Intravenous repeating dose

  • Intravenous repeating dose

  • DrugPlacebo

    Intravenous repeating dose

06

What researchers measure

Primary outcomes

  1. Number of Participants With Major Clinical Response (MCR)

    Time frame: Week 48

  2. Number of Participants With Partial Clinical Response (PCR)

    Time frame: Week 48

  3. Number of Non-responders (NR)

    Time frame: Week 48

Secondary outcomes

  1. Number of Participants Who Achieved a BILAG Score of C or Better at Week 24.

    Time frame: Week 24

  2. Time Adjusted Mean SLEDAI-2K Score

    Time frame: Week 48

  3. Annualized Flare Rate

    Time frame: Week 48 to Week 96

  4. Time to First Moderate to Severe Flare

    Time frame: Week 48 to Week 96

  5. Number of Participants Who Achieved A Major Or Partial Clinical Response At Week 48 (PCR Plus MCR Proportion), Who Did Not Experience A Flare Before Week 96

    Time frame: Week 48 to Week 96

  6. Number of Participants Who Achieved A MCR At Week 48, Who Did Not Experience A Flare Before Week 72

    Time frame: Week 48 to Week 72

  7. Number of Participants Achieved A MCR At Week 48, Who Did Not Experience A Flare Before Week 96

    Time frame: Week 48 to Week 96

  8. Change in SF-36 Subscale And Summary Scores From Baseline At Week 48

    Time frame: Baseline, Week 48

  9. Change In FACIT-Fatigue Assessment From Baseline To Week 48

    Time frame: Baseline, Week 48

  10. Change From Baseline In Pain Quality And Impact Of Pain On Daily Function Measured By The Brief Pain Inventory Short Form At Week 48

    Time frame: Baseline, Week 48

  11. The EQ-5D Single Index Utility Score At Week 48

    Time frame: Baseline, Week 48

  12. Number of Participants With Adverse Events

    Time frame: Up to 2.5 years

07

Results

Posted Sep 17, 2020
Limitations and caveats
The study was terminated before any patients reached the Week 48 visit. Therefore, the safety analysis included all safety data for the 33 randomized patients that were available up to the data cutoff date (22 March 2010)

Participant flow

A maximum screening window of 14 days was allowed.

Participant flow — Overall Study
MilestoneOcrelizumab 1000 mgOcrelizumab 400 mgPlacebo
Started121110
Completed551
Not completed769
Withdrew: Fail to return200
Withdrew: Withdrawal by subject040
Withdrew: Death020
Withdrew: Did not cooperate101
Withdrew: Administrative408

Outcome measures

PrimaryNumber of Participants With Major Clinical Response (MCR)
Time frame:
Week 48

No measurements were reported for this outcome.

PrimaryNumber of Participants With Partial Clinical Response (PCR)
Time frame:
Week 48

No measurements were reported for this outcome.

PrimaryNumber of Non-responders (NR)
Time frame:
Week 48

No measurements were reported for this outcome.

SecondaryNumber of Participants Who Achieved a BILAG Score of C or Better at Week 24.
Time frame:
Week 24

No measurements were reported for this outcome.

SecondaryTime Adjusted Mean SLEDAI-2K Score
Time frame:
Week 48

No measurements were reported for this outcome.

SecondaryAnnualized Flare Rate
Time frame:
Week 48 to Week 96

No measurements were reported for this outcome.

SecondaryTime to First Moderate to Severe Flare
Time frame:
Week 48 to Week 96

No measurements were reported for this outcome.

SecondaryNumber of Participants Who Achieved A Major Or Partial Clinical Response At Week 48 (PCR Plus MCR Proportion), Who Did Not Experience A Flare Before Week 96
Time frame:
Week 48 to Week 96

No measurements were reported for this outcome.

SecondaryNumber of Participants Who Achieved A MCR At Week 48, Who Did Not Experience A Flare Before Week 72
Time frame:
Week 48 to Week 72

No measurements were reported for this outcome.

SecondaryNumber of Participants Achieved A MCR At Week 48, Who Did Not Experience A Flare Before Week 96
Time frame:
Week 48 to Week 96

No measurements were reported for this outcome.

SecondaryChange in SF-36 Subscale And Summary Scores From Baseline At Week 48
Time frame:
Baseline, Week 48

No measurements were reported for this outcome.

SecondaryChange In FACIT-Fatigue Assessment From Baseline To Week 48
Time frame:
Baseline, Week 48

No measurements were reported for this outcome.

SecondaryChange From Baseline In Pain Quality And Impact Of Pain On Daily Function Measured By The Brief Pain Inventory Short Form At Week 48
Time frame:
Baseline, Week 48

No measurements were reported for this outcome.

SecondaryThe EQ-5D Single Index Utility Score At Week 48
Time frame:
Baseline, Week 48

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events
Time frame:
Up to 2.5 years

No measurements were reported for this outcome.

Adverse events

Collected over Baseline up to 42 months.. Non-serious events are listed at a 0.05% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/10 (0%)5/10 (50%)
Ocrelizumab 400 mg—6/11 (54.5%)10/11 (90.9%)
Ocrelizumab 1000 mg—3/12 (25%)8/12 (66.7%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPlaceboOcrelizumab 400 mgOcrelizumab 1000 mg
CYTOMEGALOVIRUSInfections and infestations0/101/110/12
CHORIORETINITISInfections and infestations0/101/110/12
PNEUMONIAInfections and infestations0/101/110/12
SEPTIC SHOCKInfections and infestations0/101/110/12
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations0/101/110/12
URINARY TRACT INFECTIONInfections and infestations0/101/110/12
NEPHROTIC SYNDROMERenal and urinary disorders0/101/110/12
RENAL FAILURERenal and urinary disorders0/101/110/12
ANAEMIABlood and lymphatic system disorders0/101/110/12
THROMBOCYTOPENIABlood and lymphatic system disorders0/101/110/12
Most frequent other events
Showing 10 of 98
Most frequent other events
EventPlaceboOcrelizumab 400 mgOcrelizumab 1000 mg
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations2/103/112/12
URINARY TRACT INFECTIONInfections and infestations1/103/111/12
DIARRHOEAGastrointestinal disorders0/103/111/12
BRONCHITISInfections and infestations0/100/113/12
SINUSITISInfections and infestations0/102/111/12
NAUSEAGastrointestinal disorders1/102/111/12
VOMITINGGastrointestinal disorders1/102/110/12
HEADACHENervous system disorders1/102/111/12
INSOMNIAPsychiatric disorders0/102/112/12
INFUSION RELATED REACTIONGeneral disorders0/102/111/12

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboOcrelizumab 400 mgOcrelizumab 1000 mgTotal
Mean41.0 ± 13.8240.2 ± 8.8036.3 ± 11.3139.0 ± 11.24
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboOcrelizumab 400 mgOcrelizumab 1000 mgTotal
Female9111030
Male1023
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboOcrelizumab 400 mgOcrelizumab 1000 mgTotal
Hispanic or Latino62412
Not Hispanic or Latino49821
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboOcrelizumab 400 mgOcrelizumab 1000 mgTotal
American Indian or Alaska Native4138
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American1124
White58720
More than one race0000
Unknown or Not Reported0000
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2007 to primary completion in Jul 2011, 42 months.

Results were first posted in Sep 2020, 9 years 2 months after primary completion. A results delay was requested in Jan 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2007
First posted
Oct 5, 2007
StartActual
Dec 19, 2007
Primary completionActual
Jul 12, 2011
CompletionActual
Jul 12, 2011
Results delay requested
Jan 17, 2013
Results first posted
Sep 17, 2020
Last update
Sep 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00539838
Lead sponsor
Genentech, Inc.
Collaborators
Roche Pharma AG
Responsible party
Sponsor
First posted
Oct 5, 2007
Start date
Dec 19, 2007
Primary completion
Jul 12, 2011
Completion
Jul 12, 2011
Results posted
Sep 17, 2020
Last update
Sep 17, 2020

Study contacts

Jorn Drappa, M.D., Ph.D.
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion